This study centers on the experimental broad‐spectrum DPP inhibitor BXCL701 (also named VbP, PT‐100, or Talabostat) that was recently assigned orphan drug designation for the treatment of AML by the FDA, and is based on recent findings showing that VbP/BXCL701 and more selective DPP8/DPP9 inhibitors are potent inducers of pyroptosis in AML cell lines and in primary AML samples from patients.164. The gene discussed is DPP9; the disease is acute myeloid leukemia.